IL122162A - Crystalline form iii atorvastatin and pharmaceutical composition containing it - Google Patents
Crystalline form iii atorvastatin and pharmaceutical composition containing itInfo
- Publication number
- IL122162A IL122162A IL12216296A IL12216296A IL122162A IL 122162 A IL122162 A IL 122162A IL 12216296 A IL12216296 A IL 12216296A IL 12216296 A IL12216296 A IL 12216296A IL 122162 A IL122162 A IL 122162A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- crystalline form
- form iii
- composition containing
- iii atorvastatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL128863A IL128863A (en) | 1995-07-17 | 1996-07-11 | Crystalline form III hydrate of [R * R *) - R)] - 2 - (4 - fluorophenyl) - ß - δ - dihydroxy - 5 - (1 - methylethyl) - 3 - phenyl - 4 - ([phenylamino) carbonyl ] - HI Pyrrole - 1 - Leptic acid hydrochloric acid (autorbastatin) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US145495P | 1995-07-17 | 1995-07-17 | |
PCT/US1996/011367 WO1997003958A1 (en) | 1995-07-17 | 1996-07-08 | Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Publications (2)
Publication Number | Publication Date |
---|---|
IL122162A0 IL122162A0 (en) | 1998-04-05 |
IL122162A true IL122162A (en) | 1999-07-14 |
Family
ID=21696105
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12216296A IL122162A (en) | 1995-07-17 | 1996-07-08 | Crystalline form iii atorvastatin and pharmaceutical composition containing it |
IL128863A IL128863A (en) | 1995-07-17 | 1996-07-11 | Crystalline form III hydrate of [R * R *) - R)] - 2 - (4 - fluorophenyl) - ß - δ - dihydroxy - 5 - (1 - methylethyl) - 3 - phenyl - 4 - ([phenylamino) carbonyl ] - HI Pyrrole - 1 - Leptic acid hydrochloric acid (autorbastatin) |
IL177378A IL177378A0 (en) | 1995-07-17 | 2006-08-08 | Form iii crystalline (r-r*r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methylethyl)3-phenyl-4-(phenylamino)carbonyl)-ih-pyrrole-1-heptanoic acid hemi calcium salt ( atorvastatin) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL128863A IL128863A (en) | 1995-07-17 | 1996-07-11 | Crystalline form III hydrate of [R * R *) - R)] - 2 - (4 - fluorophenyl) - ß - δ - dihydroxy - 5 - (1 - methylethyl) - 3 - phenyl - 4 - ([phenylamino) carbonyl ] - HI Pyrrole - 1 - Leptic acid hydrochloric acid (autorbastatin) |
IL177378A IL177378A0 (en) | 1995-07-17 | 2006-08-08 | Form iii crystalline (r-r*r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methylethyl)3-phenyl-4-(phenylamino)carbonyl)-ih-pyrrole-1-heptanoic acid hemi calcium salt ( atorvastatin) |
Country Status (33)
Country | Link |
---|---|
US (1) | US6121461A (hu) |
JP (1) | JP3296563B2 (hu) |
KR (1) | KR100431039B1 (hu) |
CN (1) | CN1081632C (hu) |
AT (1) | ATE207465T1 (hu) |
AU (1) | AU725368B2 (hu) |
BG (1) | BG63629B1 (hu) |
BR (1) | BR9610567A (hu) |
CA (1) | CA2220458C (hu) |
CO (1) | CO4700442A1 (hu) |
CZ (1) | CZ294109B6 (hu) |
DK (1) | DK0848704T3 (hu) |
EA (1) | EA000505B1 (hu) |
EE (1) | EE03607B1 (hu) |
ES (1) | ES2166456T3 (hu) |
GE (1) | GEP20002028B (hu) |
HK (1) | HK1018053A1 (hu) |
HR (1) | HRP960313B1 (hu) |
HU (1) | HU223598B1 (hu) |
ID (1) | ID16158A (hu) |
IL (3) | IL122162A (hu) |
MX (1) | MX9708857A (hu) |
MY (1) | MY118398A (hu) |
NO (1) | NO309899B1 (hu) |
NZ (1) | NZ312906A (hu) |
PE (1) | PE1798A1 (hu) |
PL (1) | PL192244B1 (hu) |
RO (1) | RO120068B1 (hu) |
SK (1) | SK284201B6 (hu) |
TW (1) | TW401399B (hu) |
UA (1) | UA44796C2 (hu) |
WO (1) | WO1997003958A1 (hu) |
ZA (1) | ZA966045B (hu) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
SI0848705T1 (en) | 1995-07-17 | 2002-04-30 | Warner-Lambert Company | Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
IN191236B (hu) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
ES2349364T3 (es) * | 1999-11-17 | 2010-12-30 | Teva Pharmaceutical Industries, Ltd. | Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica. |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
ES2252088T3 (es) | 1999-12-17 | 2006-05-16 | Pfizer Science And Technology Ireland Limited | Procedimiento de produccion a escala industrial de la hemisal de calcio de la atorvastatina trihidrato cristalina. |
AU780247B2 (en) * | 1999-12-17 | 2005-03-10 | Pfizer Science And Technology Ireland Limited | A process for producing crystalline atorvastatin calcium |
EP1332130A4 (en) * | 2000-11-03 | 2004-01-21 | Teva Pharma | HEMICALCIC ATORVASTATIN FORM VII |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
LT5196B (lt) | 2000-11-30 | 2005-02-25 | Teva Pharmaceutical Industries Ltd. | Naujos atorvastatino pusiau kalcio kristalinės formos ir jų gavimo būdai, taip pat ir nauji kitų formų gavimo būdai |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
HUP0302519A3 (en) | 2000-12-27 | 2008-10-28 | Teva Pharma | Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
EP1724256A3 (en) | 2001-01-09 | 2007-03-21 | Warner-Lambert Company LLC | Novel process for the synthesis of 5-(4-fluorphenyl)-1-2(2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl)-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
UA74075C2 (en) * | 2001-06-29 | 2005-10-17 | Warner Lambert Co | NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS) |
JP2005500351A (ja) * | 2001-07-30 | 2005-01-06 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 結晶形態viおよびviiのアトルバスタチンカルシウム |
US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
ES2304140T3 (es) * | 2001-08-03 | 2008-09-16 | Ciba Holding Inc. | Formas cristalinas de sodio de fluvastatina. |
US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
EP1480950A4 (en) * | 2002-02-15 | 2005-05-18 | Teva Pharma | NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX |
CA2475123A1 (en) * | 2002-02-19 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Desolvating solvates of atorvastatin hemi-calcium |
CZ2004943A3 (cs) * | 2002-03-18 | 2005-02-16 | Biocon Limited | Amorfní HMG-CoA inhibitory obsahující reduktázu s požadovanou velikostí částic |
ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
RS20050105A (en) * | 2002-08-06 | 2007-11-15 | Warner-Lambert Company Llc., | Process for preparing 5-(4-(54) fluorophenyl)-1-(2-((2r,4r)-4- hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl)- 2-isopropyl-4- phenyl-1h-pyrrole-3- carboxylic acid phenylamide |
CA2491051A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
SI21302A (sl) | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
HRP20020885B1 (en) * | 2002-11-11 | 2007-05-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A |
EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
RS20050760A (sr) * | 2003-04-14 | 2008-04-04 | Warner-Lambert Company Llc., | Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline |
US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
CN101318923A (zh) * | 2003-09-17 | 2008-12-10 | 沃尼尔·朗伯有限责任公司 | [R-(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸的结晶形式 |
MXPA06011987A (es) * | 2004-04-16 | 2007-01-16 | Pfizer Prod Inc | Procedimiento para formar calcio de atorvastatina amorfa. |
ES2739493T3 (es) | 2004-05-05 | 2020-01-31 | Pfizer Prod Inc | Formas de sal de de atorvastatina con benetamina |
AU2005263550C1 (en) * | 2004-07-16 | 2013-01-17 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
EP1771412A2 (en) | 2004-07-20 | 2007-04-11 | Warner-Lambert Company LLC | Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1) |
JP2008510798A (ja) | 2004-08-27 | 2008-04-10 | バイオコン・リミテッド | 非晶質アトルバスタチンカルシウムのための方法 |
TWI321132B (en) | 2004-09-28 | 2010-03-01 | Teva Pharma | Process for preparing forms of atorvastatin calcium substantially free of impurities |
MX2007004425A (es) | 2004-10-18 | 2007-06-07 | Teva Pharma | Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente. |
CN101048141A (zh) | 2004-10-28 | 2007-10-03 | 沃尼尔·朗伯有限责任公司 | 形成非晶形的阿托伐他汀的方法 |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
AU2005305460B2 (en) | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
JP2008521878A (ja) * | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 非晶質アトルバスタチンの医薬組成物及びその製造のための方法 |
GB2424880A (en) * | 2005-04-06 | 2006-10-11 | Generics | Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase |
CA2547216A1 (en) * | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
US8084488B2 (en) * | 2005-11-21 | 2011-12-27 | Pfizer Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium |
TW200745026A (en) | 2005-12-13 | 2007-12-16 | Teva Pharma | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
EP1877375A1 (en) * | 2006-03-01 | 2008-01-16 | Teva Pharmaceutical Industries Ltd | Process for preparing a crystalline form of atorvastatin hemi-calcium |
US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
KR100878140B1 (ko) * | 2007-01-29 | 2009-01-12 | 한미약품 주식회사 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
US20100260851A1 (en) * | 2007-07-11 | 2010-10-14 | Actavis Group Ptc Ehf | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium |
WO2009013633A2 (en) * | 2007-07-20 | 2009-01-29 | Actavis Group Ptc Ehf | Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts |
DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
US20090124817A1 (en) * | 2007-11-09 | 2009-05-14 | The Industry & Academic Cooperation In Chungnam National University | Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles |
US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
CN103274985B (zh) * | 2010-12-03 | 2016-03-09 | 上海科州药物研发有限公司 | 一种阿托伐他汀氨基酸盐 |
US9050342B2 (en) | 2011-03-29 | 2015-06-09 | Pfizer Inc. | Beneficial effects of combination therapy on cholesterol |
CN103702982A (zh) * | 2011-07-01 | 2014-04-02 | 中化帝斯曼制药有限公司荷兰公司 | 阿托伐他汀半钙的超细晶体 |
CN103483238B (zh) * | 2013-08-20 | 2014-12-31 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钙三水合物的制备方法 |
CN106432033B (zh) * | 2016-10-21 | 2018-07-27 | 江苏阿尔法药业有限公司 | 一种无定形阿托伐他汀钙的制备方法 |
KR101723783B1 (ko) | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE409281C (de) * | 1922-04-26 | 1925-01-31 | Farbenfab Vorm Bayer F & Co | Verfahren zur Herstellung von sauren Monoazofarbstoffen fuer Wolle |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
CA2150372C (en) * | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
-
1996
- 1996-07-03 HR HR960313A patent/HRP960313B1/xx not_active IP Right Cessation
- 1996-07-08 WO PCT/US1996/011367 patent/WO1997003958A1/en active Application Filing
- 1996-07-08 CA CA002220458A patent/CA2220458C/en not_active Expired - Lifetime
- 1996-07-08 AT AT96924367T patent/ATE207465T1/de not_active IP Right Cessation
- 1996-07-08 CZ CZ1998123A patent/CZ294109B6/cs not_active IP Right Cessation
- 1996-07-08 GE GEAP19964148A patent/GEP20002028B/en unknown
- 1996-07-08 CN CN96195632A patent/CN1081632C/zh not_active Expired - Lifetime
- 1996-07-08 NZ NZ312906A patent/NZ312906A/xx not_active IP Right Cessation
- 1996-07-08 HU HU9901687A patent/HU223598B1/hu active IP Right Grant
- 1996-07-08 RO RO98-00059A patent/RO120068B1/ro unknown
- 1996-07-08 DK DK96924367T patent/DK0848704T3/da active
- 1996-07-08 JP JP50670997A patent/JP3296563B2/ja not_active Expired - Lifetime
- 1996-07-08 BR BR9610567A patent/BR9610567A/pt not_active Application Discontinuation
- 1996-07-08 MX MX9708857A patent/MX9708857A/es active IP Right Grant
- 1996-07-08 EE EE9800016A patent/EE03607B1/xx unknown
- 1996-07-08 SK SK59-98A patent/SK284201B6/sk not_active IP Right Cessation
- 1996-07-08 AU AU64841/96A patent/AU725368B2/en not_active Expired
- 1996-07-08 IL IL12216296A patent/IL122162A/xx not_active IP Right Cessation
- 1996-07-08 ES ES96924367T patent/ES2166456T3/es not_active Expired - Lifetime
- 1996-07-08 EA EA199800129A patent/EA000505B1/ru not_active IP Right Cessation
- 1996-07-08 PL PL324532A patent/PL192244B1/pl unknown
- 1996-07-08 KR KR10-1998-0700347A patent/KR100431039B1/ko not_active IP Right Cessation
- 1996-07-10 TW TW085108326A patent/TW401399B/zh not_active IP Right Cessation
- 1996-07-11 IL IL128863A patent/IL128863A/en not_active IP Right Cessation
- 1996-07-15 ID IDP962021A patent/ID16158A/id unknown
- 1996-07-16 ZA ZA9606045A patent/ZA966045B/xx unknown
- 1996-07-16 MY MYPI96002920A patent/MY118398A/en unknown
- 1996-07-17 CO CO96037513A patent/CO4700442A1/es unknown
- 1996-07-17 PE PE1996000540A patent/PE1798A1/es not_active Application Discontinuation
- 1996-08-07 UA UA98020825A patent/UA44796C2/uk unknown
-
1998
- 1998-01-14 BG BG102186A patent/BG63629B1/bg unknown
- 1998-01-16 NO NO980208A patent/NO309899B1/no not_active IP Right Cessation
- 1998-12-15 HK HK98113381A patent/HK1018053A1/xx not_active IP Right Cessation
-
1999
- 1999-07-26 US US09/360,778 patent/US6121461A/en not_active Expired - Lifetime
-
2006
- 2006-08-08 IL IL177378A patent/IL177378A0/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL122162A (en) | Crystalline form iii atorvastatin and pharmaceutical composition containing it | |
NZ312907A (en) | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl | |
EP3009423A3 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) | |
HK1018054A1 (en) | Novel process for the production of amorphous -[r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) | |
CA2521908A1 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NP | Permission for amending the patent specification granted (section 66, patents law 1967) | ||
NP | Permission for amending the patent specification granted (section 66, patents law 1967) |
Free format text: JOURNAL NO. 4/2001P. 1751, 1752, 1753 NOTICES PATENT APPLICATION NO. 122162, 122161, 122118 DELETE THE ABOVE NOTICES. THE NOTICES WERE PUBLISHED BEFORE PAYMENT OF PUBLICATION FEES. THE NOTICES ARE BEING REPUBLISHED IN THIS JOURNAL. |
|
NP | Permission for amending the patent specification granted (section 66, patents law 1967) | ||
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |